Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Phytother Res. 2024 Oct;38(10):4940-4956. doi: 10.1002/ptr.7788. Epub 2023 Mar 21.
Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone secreted by K cells in the small intestine and is considered an obesity-promoting factor. In this study, we systematically investigated the anti-obesity effects of intragastric safflower yellow (SY)/hydroxysafflor yellow A (HSYA) and the underlying mechanism for the first time. Our results showed that intragastric SY/HSYA, rather than an intraperitoneal injection, notably decreased serum GIP levels and GIP staining in the small intestine in diet-induced obese (DIO) mice. Moreover, intragastric SY/HSYA was also first found to significantly suppress GIP receptor (GIPR) signaling in both the hypothalamus and subcutaneous White adipose tissue. Our study is the first to show that intragastric SY/HSYA obviously reduced food intake and body weight gain in leptin sensitivity experiments and decreased serum leptin levels in DIO mice. Further experiments demonstrated that SY treatment also significantly reduced leptin levels, whereas the inhibitory effect of SY on leptin levels was reversed by activating GIPR in 3 T3-L1 adipocytes. In addition, intragastric SY/HSYA had already significantly reduced serum GIP levels and GIPR expression before the serum leptin levels were notably changed in high-fat-diet-fed mice. These findings suggested that intragastric SY/HSYA may alleviate diet-induced obesity in mice by ameliorating hyperleptinemia via dual inhibition of the GIP-GIPR axis.
葡萄糖依赖性胰岛素多肽 (GIP) 是一种由小肠 K 细胞分泌的胃肠激素,被认为是促进肥胖的因素。在这项研究中,我们首次系统地研究了口服红花黄色素 (SY)/羟基红花黄色素 A (HSYA) 的抗肥胖作用及其潜在机制。我们的研究结果表明,与腹腔注射相比,口服 SY/HSYA 可显著降低饮食诱导肥胖 (DIO) 小鼠的血清 GIP 水平和小肠 GIP 染色。此外,我们首次发现口服 SY/HSYA 还可显著抑制下丘脑和皮下白色脂肪组织中的 GIP 受体 (GIPR) 信号。本研究首次表明,口服 SY/HSYA 可明显减少瘦素敏感实验中的摄食量和体重增加,并降低 DIO 小鼠的血清瘦素水平。进一步的实验表明,SY 处理也显著降低了瘦素水平,而在 3T3-L1 脂肪细胞中激活 GIPR 可逆转 SY 对瘦素水平的抑制作用。此外,在高脂肪饮食喂养的小鼠中,血清瘦素水平明显改变之前,口服 SY/HSYA 已显著降低了血清 GIP 水平和 GIPR 表达。这些发现表明,口服 SY/HSYA 可能通过双重抑制 GIP-GIPR 轴改善高胰岛素血症来减轻小鼠的饮食诱导肥胖。